Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2011

View Archived Issues

Dominant negative CXCL8 (IL-8) mutant reduces renal allograft damage

Switching from agalsidase beta to agalsidase alfa feasible for Fabry's disease

Eisai receives European approval for Halaven in advanced breast cancer

Preliminary data from phase III trial support feasibility of rHuPH20-faciliated IGSC therapy

NeuroPhage plans phase I study of bacteriophage NPT-001 in Alzheimer's disease

Personalized peptide vaccine shows promise in patients with resistant urothelial carcinoma

Theravida's THVD-201 reduces symptoms of dry mouth in phase I trial in OAB, phase II study under way

Efficacy of botulinum toxin type A in idiopathic detrusor overactivity confirmed in large study

Potential new biomarker for chronic rhinosinusitis with nasal polyps identified / News in Context

Portsmouth Technologies patents novel hydroxamate histone deacetylase inhibitors

Synageva BioPharma receives funding for SBC-102 in lysosomal acid lipase deficiency

Cellular Dynamics and Roche form standard supply agreement for iCell Cardiomyocytes

OncoTherapy Science initiates gastric cancer vaccine trial in Singapore

Takeda launches Reminyl for dementia of the Alzheimer's type in Japan

Phase I/II results for InSite Vision's ISV-303 encouraging for cataract postsurgery pain

Xoma reports phase II data for XOMA-052 in type 2 diabetes

Starpharma completes all patient follow-up visits in phase II trial of VivaGel

SYGNIS to continue phase II AXIS 2 study of AX-200 in acute ischemic stroke

Ambrilia Biopharma enters into agreement with ZBx for PSP-94

Rexahn reaches 33% enrollment in phase IIb trial of Serdaxin in major depressive disorder

Takeda submits Japanese NDA for TAK-536 in hypertension

Phase III elvitegravir trial in HIV meets primary objective

Graceway receives Canadian approval for topical genital warts treatment Vyloma 3.75%

KaloBios begins phase I trial of anti-EphA3 monoclonal antibody in hematologic malignancies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.